1. Mayr, L. M.; Fuerst, P. The future of high-throughput screening. Journal of Biomolecular Screening 2008, 13, 443-8.
2. Pereira, D. A.; Williams, J. A. Origin and evolution of high throughput screening. British Journal of Pharmacology 2007, 152, 53-61.
3. Shoichet, B. K. Screening in a spirit haunted world. Drug Discovery Today 2006, 11, 607-15.
4. McGovern, S. L.; Caselli, E.; Grigorieff, N.; Shoichet, B. K. A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. Journal of Medicinal Chemistry 2002, 45, 1712-22.
5. McGovern, S. L.; Helfand, B. T.; Feng, B.; Shoichet, B. K. A specific mechanism of nonspecific inhibition. Journal of Medicinal Chemistry 2003, 46, 4265-72.
6. Jönsson, U.; Fägerstam, L.; Ivarsson, B.; Johnsson, B.; Karlsson, R.; Lundh, K.; Löfås, S.; Persson, B.; Roos, H.; Rönnberg, I. Real-time biospecific interaction analysis using surface plasmon resonance and a sensor chip technology. BioTechniques 1991, 11, 620-7.
7. Karlsson, R. SPR for molecular interaction analysis: a review of emerging application areas. Journal of Molecular Recognition 2004, 17, 151-61.
8. Giannetti, A. M.; Koch, B. D.; Browner, M. F. Surface plasmon resonance based assay for the detection and characterization of promiscuous inhibitors. Journal of Medicinal Chemistry 2008, 51, 574-80.
9. Simard, J. R.; Grütter, C.; Pawar, V.; Aust, B.; Wolf, A.; Rabiller, M.; Wulfert, S.; Robubi, A.; Klüter, S.; Ottmann, C.; Rauh, D. High-throughput screening to identify inhibitors which stabilize inactive kinase conformations in p38alpha. Journal of the American Chemical Society 2009, 131, 18478-88.
10. Simard, J. R.; Rauh, D. FLiK: a direct-binding assay for the identification and kinetic characterization of stabilizers of inactive kinase conformations. Methods in Enzymology 2014, 548, 147-71.
11. Cohen, B. E.; Pralle, A.; Yao, X.; Swaminath, G.; Gandhi, C. S.; Jan, Y. N.; Kobilka, B. K.; Isacoff, E. Y.; Jan, L. Y. A fluorescent probe designed for studying protein conformational change. Proceedings of the National Academy of Sciences of the United States of America 2005, 102, 965-70.
12. Hibbs, R. E.; Talley, T. T.; Taylor, P. Acrylodan-conjugated cysteine side chains reveal conformational state and ligand site locations of the acetylcholine-binding protein. Journal of Biological Chemistry 2004, 279, 28483-91.
13. Salafsky, J. S. Detection of protein conformational change by optical second-harmonic generation. Journal of Chemical Physics 2006, 125, 074701.
14. Moree, B.; Connell, K.; Mortensen, R. B.; Liu, C. T.; Benkovic, S. J.; Salafsky, J. Protein conformational changes are detected and resolved site specifically by second-harmonic generation. Biophysical Journal 2015, 109, 806-15.
15. Butko, M. T.; Moree, B.; Mortensen, R. B.; Salafsky, J. Detection of ligand-induced conformational changes in oligonucleotides by second-harmonic generation at a supported lipid bilayer interface. Analytical Chemistry 2016, 88, 10482-189.
16. Hendrani, A. D.; Adesiyun, T.; Quispe, R.; Jones, S. R.; Stone, N. J.; Blumenthal, R. S.; Martin, S. S. Dyslipidemia management in primary prevention of cardiovascular disease: Current guidelines and strategies. World Journal of Cardiology 2016, 8, 201-10.
17. Ohashi, R.; Mu, H.; Wang, X.; Yao, Q.; Chen, C. Reverse cholesterol transport and cholesterol efflux in atherosclerosis. QJM : Monthly Journal of the Association of Physicians 2005, 98, 845-56.
18. Yazdanyar, A.; Yeang, C.; Jiang, X. C. Role of phospholipid transfer protein in high-density lipoprotein- mediated reverse cholesterol transport. Current Atherosclerosis Reports 2011, 13, 242-8.
19. Jiang, X. C. Phospholipid transfer protein: its impact on lipoprotein homeostasis and atherosclerosis. Journal of Lipid Research 2018, 59, 764-71.
20. Tu, A. Y.; Albers, J. J. Glucose regulates the transcription of human genes relevant to HDL metabolism: responsive elements for peroxisome proliferator-activated receptor are involved in the regulation of phospholipid transfer protein. Diabetes 2001, 50, 1851-6.
21. Urizar, N. L.; Dowhan, D. H.; Moore, D. D. The farnesoid X-activated receptor mediates bile acid activation of phospholipid transfer protein gene expression. Journal of Biological Chemistry 2000, 275, 39313-7.
22. Cao, G.; Beyer, T. P.; Yang, X. P.; Schmidt, R. J.; Zhang, Y.; Bensch, W. R.; Kauffman, R. F.; Gao, H.; Ryan, T. P.; Liang, Y.; Eacho, P. I.; Jiang, X. C. Phospholipid transfer protein is regulated by liver X receptors in vivo. Journal of Biological Chemistry 2002, 277, 39561-5.
23. Mak, P. A.; Kast-Woelbern, H. R.; Anisfeld, A. M.; Edwards, P. A. Identification of PLTP as an LXR target gene and apoE as an FXR target gene reveals overlapping targets for the two nuclear receptors. Journal of Lipid Research 2002, 43, 2037-41.
24. Okazaki, H.; Goldstein, J. L.; Brown, M. S.; Liang, G. LXR-SREBP-1c-phospholipid transfer protein axis controls very low density lipoprotein (VLDL) particle size. Journal of Biological Chemistry 2010, 285, 6801-10.
25. Riemens, S. C.; van Tol, A.; Sluiter, W. J.; Dullaart, R. P. Plasma phospholipid transfer protein activity is related to insulin resistance: impaired acute lowering by insulin in obese type II diabetic patients. Diabetologia 1998, 41, 929-34.
26. de Vries, R.; Dallinga-Thie, G. M.; Smit, A. J.; Wolffenbuttel, B. H.; van Tol, A.; Dullaart, R. P. Elevated plasma phospholipid transfer protein activity is a determinant of carotid intima-media thickness in type 2 diabetes mellitus. Diabetologia 2006, 49, 398-404.
27. Jiang, X. C.; Jin, W.; Hussain, M. M. The impact of phospholipid transfer protein (PLTP) on lipoprotein metabolism. Nutrition & Metabolism 2012, 9, 75.
28. Jiang, X. C.; Qin, S.; Qiao, C.; Kawano, K.; Lin, M.; Skold, A.; Xiao, X.; Tall, A. R. Apolipoprotein B secretion and atherosclerosis are decreased in mice with phospholipid-transfer protein deficiency. Nature Medicine 2001, 7, 847-52.
29. Yang, X. P.; Yan, D.; Qiao, C.; Liu, R. J.; Chen, J. G.; Li, J.; Schneider, M.; Lagrost, L.; Xiao, X.; Jiang, X. C. Increased atherosclerotic lesions in apoE mice with plasma phospholipid transfer protein overexpression. Arteriosclerosis, Thrombosis, and Vascular Biology 2003, 23, 1601-7.
30. Luo, Y.; Shelly, L.; Sand, T.; Reidich, B.; Chang, G.; Macdougall, M.; Peakman, M. C.; Jiang, X. C. Pharmacologic inhibition of phospholipid transfer protein activity reduces apolipoprotein-B secretion from hepatocytes. Journal of Pharmacology and Experimental Therapeutics 2010, 332, 1100-6.
31. Okamoto, H.; Iwamoto, Y.; Maki, M. Sotani, T.; Yonemori, F.; Wakitani, K. Effect of JTT-705 on cholesteryl ester transfer protein and plasma lipid levels in normolipidemic animals. European Journal of Pharmacology 2003, 466, 147-54.
32. Zhang, J. H.; Chung, T. D.; Oldenburg, K. R. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. Journal of Biomolecular Screening 1999, 4, 67-73.
33. Meex, S. J.; Andreo, U.; Sparks, J. D.; Fisher, E. A. Huh-7 or HepG2 cells: which is the better model for studying human apolipoprotein-B100 assembly and secretion? Journal of Lipid Research 2011, 52, 152-8.
34. Rader, D. J.; Tall, A. R. The not-so-simple HDL story: Is it time to revise the HDL cholesterol hypothesis? Nature Medicine 2012, 18, 1344-6.
35. Tariq, S. M.; Sidhu, M. S.; Toth, P. P.; Boden, W. E. HDL hypothesis: where do we stand now? Current Atherosclerosis Reports 2014, 16, 398.
36. Shelly, L.; Royer, L.; Sand, T.; Jensen, H.; Luo, Y. Phospholipid transfer protein deficiency ameliorates diet-induced hypercholesterolemia and inflammation in mice. Journal of Lipid Research 2008, 49, 773-81.
37. Brehm, A.; Geraghty, P.; Campos, M.; Garcia-Arcos, I.; Dabo, A. J., Gaffney, A.; Eden, E.; Jiang, X. C.; D'Armiento, J.; Foronjy, R. Cathepsin G degradation of phospholipid transfer protein (PLTP) augments pulmonary inflammation. FASEB Journal 2014, 28, 2318-31.
38. Yu, Y.; Cui, Y.; Zhao, Y.; Liu, S.; Song, G.; Jiao, P.; Li, B.; Luo, T.; Guo, S.; Zhang, X.; Wang, H.; Jiang, X. C.; Qin, S. The binding capability of plasma phospholipid transfer protein, but not HDL pool size, is critical to repress LPS induced inflammation. Scientific Reports 2016, 6, 20845.
39. Audo, R.; Deckert, V.; Daien, C. I.; Che, H.; Elhmioui, J.; Lemaire, S.; Pais de Barros, J. P.; Desrumaux, C.; Combe, B.; Hahne, M.; Lagrost, L.; Morel, J. PhosphoLipid transfer protein (PLTP) exerts a direct pro-inflammatory effect on rheumatoid arthritis (RA) fibroblasts-like-synoviocytes (FLS) independently of its lipid transfer activity. PloS One 2018, 13, e0193815.
40. Hogarth, C. A.; Roy, A.; Ebert, D. L. Genomic evidence for the absence of a functional cholesteryl ester transfer protein gene in mice and rats. Comparative Biochemistry and Physiology - Part B: Biochemistry & Molecular Biology 2003, 135, 219-29.
41. Kaur, M.; Bahia, M. S.; Silakari, O. Inhibitors of interleukin-2 inducible T-cell kinase as potential therapeutic candidates for the treatment of various inflammatory disease conditions. European Journal of Pharmaceutical Sciences 2012, 47, 574-88.
42. Gomez-Rodriguez, J.; Kraus, Z. J.; Schwartzberg, P. L. Tec family kinases Itk and Rlk/ Txk in T lymphocytes: cross-regulation of cytokine production and T-cell fates. FEBS Journal 2011, 278, 1980-9.
43. Bryan, M. C.; Rajapaksa, N. S. Kinase inhibitors for the treatment of immunological disorders: recent advances. Journal of Medicinal Chemistry 2018, 61, 9030-58.
44. Knighton, D. R.; Zheng, J. H.; Ten Eyck, L. F.; Ashford, V. A.; Xuong, N. H.; Taylor, S. S.; Sowadski, J. M. Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase. Science 1991, 253, 407-14.
45. Karaman, M. W.; Herrgard, S.; Treiber, D. K.; Gallant, P.; Atteridge, C. E.; Campbell, B. T.; Chan, K. W.; Ciceri, P.; Davis, M. I.; Edeen, P. T., Faraoni,;R.; Floyd, M,; Hunt, J. P.; Lockhart, D. J,; Milanov, Z. V.; Morrison, M. J.; Patel, H. K.; . Pritchard, S.; Wodicka, L. M., Zarrinkar, P. P. A quantitative analysis of kinase inhibitor selectivity. Nature Biotechnology 2008, 26, 127-32.
46. Kornev, A. P.; Haste, N. M.; Taylor, S. S.; Eyck, L. F. Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism. Proceedings of the National Academy of Sciences of the United States of America 2006, 103, 17783-8.
47. Vijayan, R. S.; He, P.; Modi, V.; Duong-Ly, K. C.; Ma, H.; Peterson, J. R.; Dunbrack, R. L. Jr.; Levy, R. M. Conformational analysis of the DFG-out kinase motif and biochemical profiling of structurally validated type II inhibitors. Journal of Medicinal Chemistry 2015, 58, 466-79.
48. Imamura, M.; Kumagai, K.; Nakano, H.; Okabe, T.; Nagano, T.; Kojima, H. Inexpensive high-throughput screening of kinase inhibitors using one-step enzyme-coupled fluorescence assay for ADP detection. SLAS Discovery 2019, 24, 284-94.
49. Ahmad, S.; St Hilaire, V. R.; Dandepally, S. R.; Johnson, G. L.; Williams, A. L.; Scott, J. E. Discovery and characterization of an iminocoumarin scaffold as an inhibitor of MEKK2 (MAP3K2). Biochemical and Biophysical Research Communications 2018, 496, 205-11.
50. Lebakken, C. S.; Riddle, S. M.; Singh, U.; Frazee, W. J.; Eliason, H. C.; Gao, Y.; Reichling, L. J.; Marks, B. D.; Vogel, K. W. Development and applications of a broad-coverage, TR-FRET-based kinase binding assay platform. Journal of Biomolecular Screening 2009, 14, 924-35.
51. Wang, W.; Krosky, D.; Ahn, K. Discovery of inactive conformation-selective kinase inhibitors by utilizing cascade assays. Biochemistry 2017, 56, 4449-56.
52. Hantani, Y.; Iio, K.; Hantani, R.; Umetani, K.; Sato, T.; Young, T.; Connell, K.; Kintz, S.; Salafsky, J. Identification of inactive conformation-selective interleukin-2-inducible T-cell kinase (ITK) inhibitors based on second-harmonic generation. FEBS Open Bio 2018, 8, 1412-23.
53. Lin, T. A.; McIntyre, K. W.; Das, J.; Liu, C.; O’Day, K. D.; Penhallow, B.; Hung C. Y.; Whitney, G. S.; Shuster, D. J.; Yang, X.; Townsend, R.; Postelnek, J.; Spergel, S. H.; Lin, J.; Moquin, R. V.; Furch, J. A.; Kamath, A. V.; Zhang, H.; Marathe, P. H.; Perez-Villar, J. J.; Doweyko, A.; Killar, L.; Dodd, J. H.; Barrish, J. C.; Wityak, J.; Kanner, S. B. Selective Itk inhibitors block T-cell activation and murine lung inflammation. Biochemistry 2004, 43, 11056-62.
54. Zegzouti, H.; Zdanovskaia, M.; Hsiao, K.; Goueli, S. A. ADP-Glo: A bioluminescent and homogeneous ADP monitoring assay for kinases. Assay and Drug Development Technologies 2009, 7, 560-72.
55. Charrier, J. D.; Miller, A.; Kay, D. P.; Brenchley, G.; Twin, H. C.; Collier, P. N.; Ramaya, S.; Keily, S. B.; Durrant, S. J.; Knegtel, R. M.; Tanner, A. J.; Brown, K.; Curnock, A. P.; Jimenez, J. M. Discovery and structure-activity relationship of 3-aminopyrid-2-ones as potent and selective interleukin-2 inducible T-cell kinase (Itk) inhibitors. Journal of Medicinal Chemistry 2011, 54, 2341-50.
56. Pastor, R. M.; Burch, J. D.; Magnuson, S.; Ortwine, D. F.; Chen, Y.; De La Torre, K.; Ding, X.; Eigenbrot, C.; Johnson, A.; Liimatta, M.; Liu, Y.; Shia, S.; Wang, X.; Wu, L. C.; Pei, Z. Discovery and optimization of indazoles as potent and selective interleukin-2 inducible T cell kinase (ITK) inhibitors. Bioorganic & Medicinal Chemistry Letters 2014, 24, 2448-52.
57. Han, S.; Czerwinski, R. M.; Caspers, N. L.; Limburg, D. C.; Ding, W.; Wang, H.; Ohren, J. F.; Rajamohan, F.; McLellan, T. J.; Unwalla, R.; Choi, C.; Parikh, M. D.; Seth, N.; Edmonds, J.; Phillips, C.; Shakya, S.; Li, X.; Spaulding, V.; Hughes, S.; Cook, A.; Robinson, C.; Mathias, J. P.; Navratilova, I.; Medley, Q. G.; Anderson, D. R.; Kurumbail, R. G.; Aulabaugh, A. Selectively targeting an inactive conformation of interleukin-2-inducible T-cell kinase by allosteric inhibitors. Biochemical Journal 2014, 460, 211-22.
58. Navratilova, I.; Macdonald, G.; Robinson, C.; Hughes, S.; Mathias, J.; Phillips, C.; Cook, A. Biosensor-based approach to the identification of protein kinase ligands with dual-site modes of action. Journal of Biomolecular Screening 2012, 17, 183-93.
59. Axten, J. M.; Romeril, S. P.; Shu, A.; Ralph, J.; Medina, J. R.; Feng, Y.; Li, W. H.; Grant, S. W.; Heerding, D. A.; Minthorn, E.; Mencken, T.; Gaul, N.; Goetz, A.; Stanley, T.; Hassell, A. M.; Gampe, R. T.; Atkins, C.; Kumar, R. Discovery of GSK2656157: An optimized PERK inhibitor selected for preclinical development. ACS Medicinal Chemistry Letters 2013, 4, 964-8.
60. Uitdehaag, J. C.; Sünnen, C. M.; van Doornmalen, A. M.; de Rouw, N.; Oubrie, A.; Azevedo, R.; Ziebell, M.; Nickbarg, E.; Karstens, W. J.; Ruygrok,S. Multidimensional profiling of CSF1R screening hits and inhibitors: assessing cellular activity, target residence time, and selectivity in a higher throughput way. Journal of Biomolecular Screening 2011, 16, 1007-17.
61. Di Paolo, J. A.; Huang, T.; Balazs, M.; Barbosa, J.; Barck, K. H.; Bravo, B.J.; Carano, R. A.; Darrow, J.; Davies, D. R.; DeForge, L. E.; Diehl, L.; Ferrando, R.; Gallion, S. L.; Giannetti, A. M.; Gribling, P.; Hurez, V.; Hymowitz, S. G.; Jones, R.; Kropf, J. E.; Lee, W. P.; Maciejewski, P. M.;Mitchell, S. A.; Rong, H.; Staker, B. L.; Whitney, J. A.; Yeh, S.; Young, W. B.; Yu, C.; Zhang, J.; Reif, K.; Currie, K. S. Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis. Nature Chemical Biology 2011, 7, 41-50.
62. Schneider, R.; Gohla, A.; Simard, J. R.; Yadav, D. B.; Fang, Z.; van Otterlo,W. A.; Rauh, D. Overcoming compound fluorescence in the FLiK screening assay with red-shifted fluorophores. Journal of the American Chemical Society 2013, 135, 8400-8.
63. Bamborough, P.; Brown, M. J.; Christopher, J. A.; Chung, C. W.; Mellor, G.W. Selectivity of kinase inhibitor fragments. Journal of Medicinal Chemistry 2011, 54, 5131-43.
64. Kutach, A. K.; Villaseñor, A. G.; Lam, D.; Belunis, C.; Janson, C.; Lok, S.;Hong, L. N.; Liu, C. M.; Deval, J.; Novak, T. J.; Barnett, J. W.; Chu, W.; Shaw, D.; Kuglstatter, A. Crystal structures of IL-2-inducible T cell kinase complexed with inhibitors: insights into rational drug design and activity regulation. Chemical Biology & Drug Design 2010, 76, 154-63.
65. Zapf, C. W.; Gerstenberger, B. S.; Xing, L.; Limburg, D. C.; Anderson, D. R.; Caspers, N.; Han, S.; Aulabaugh, A.; Kurumbail, R.; Shakya, S.; Li, X.; Spaulding, V.; Czerwinski, R. M.; Seth, N.; Medley, Q. G. Covalent inhibitors of interleukin-2 inducible T cell kinase (Itk) with nanomolar potency in a whole-blood assay. Journal of Medicinal Chemistry 2012, 55, 10047-63.
66. Alder, C. M.; Ambler, M.; Campbell, A. J.; Champigny, A. C.; Deakin, A. M.; Harling, J. D.; Harris, C. A.; Longstaff, T.; Lynn, S.; Maxwell, A. C.;Mooney, C. J.; Scullion, C.; Singh, O. M.; Smith, I. E.; Somers, D. O.; Tame,C. J.; Wayne, G.; ilson, C.; Woolven, J. M. Identification of a novel and selective series of Itk inhibitors via a template-hopping strategy. ACS Medicinal Chemistry Letters 2013, 4, 948-52.
67. MacKinnon, C. H.; Lau, K.; Burch, J. D.; Chen, Y.; Dines, J.; Ding, X.; Eigenbrot, C.; Heifetz, A.; Jaochico, A.; Johnson, A.; Kraemer, J.; Kruger, S.; Krülle, T. M.; Liimatta, M.; Ly, J.; Maghames, R.; Montalbetti, C. A.; Ortwine, D. F.; Pérez-Fuertes, Y.; Shia, S.; Stein, D. B.; Trani, G.; Vaidya, D.; G.; Wang, X.; Bromidge, S. M.; Wu, L. C.; Pei, Z. Structure-based design and synthesis of potent benzothiazole inhibitors of interleukin-2 inducible T cell kinase (ITK). Bioorganic & Medicinal Chemistry Letters 2013, 23, 6331-5.
68. Burch, J. D.; Lau, K.; Barker, J. J.; Brookfield, F.; Chen, Y.; Chen, Y.; Eigenbrot, C.; Ellebrandt, C.; Ismaili, M. H.; Johnson, A.; Kordt, D.; MacKinnon, C. H.; McEwan, P. A.; Ortwine, D. F.; Stein, D. B.; Wang, X.; Winkler, D.; Yuen, P. W.; Zhang, Y.; Zarrin, A. A.; Pei, Z. Property- and structure-guided discovery of a tetrahydroindazole series of interleukin-2 inducible T-cell kinase inhibitors. Journal of Medicinal Chemistry 2014, 57, 5714-27.
69. McLean, L.; Zhang, Y; Zaidi, N.; Bi, X.; Wang, R.; Dharanipragada, R.; Jurcak, J. G.; Gillespy, T. A.; Zhao, Z.; Musick, K. Y.; Choi, Y. M.; Barrague, M.; Peppard, J; Smicker, M.; Duguid, M.; Parkar, A.; Fordham, J.; Kominos,D. X-ray crystallographic structure-based design of selective thienopyrazole inhibitors for interleukin-2-inducible tyrosine kinase. Bioorganic & Medicinal Chemistry Letters 2012, 22, 3296-300.
70. Schneider, R.; Beumer, C.; Simard, J. R.; Grütter, C.; Rauh, D. Selective detection of allosteric phosphatase inhibitors. Journal of the American Chemical Society 2013, 135, 6838-41.
71. Mayer-Wrangowski, S. C.; Rauh, D. Monitoring ligand-induced conformational changes for the identification of estrogen receptor agonists and antagonists. Angewandte Chemie (International ed. in English) 2015, 54, 4379-82.